Omeros Corporation ($OMER) reports quarterly and annual results

By |March 17th, 2017|Opinions|

Omeros Corporation ($OMER) reported its financial results for the fourth quarter and for the full year. The company’s revenue for the quarter stood at 412.9 million, up 94 percent on year over year basis. Its full year revenue was reported at $41.6 million, jumping 208 percent over the revenue for [...]

Premarket Biotech Digest – $GKOS receives code renewal, $EDIT prices stock offering, $SNOA reports +ve results

By |March 17th, 2017|Digest|

Glaukos Corporation ($GKOS) stocks showed an upward spike as the company that the CPT codes used by physicians for reimbursement for implanting the iStent device have been extended five years. The extension has been granted by the AMA CPT Editorial Panel. CPT codes are used by [...]

Catalyst Pharmaceuticals ($CPRX) announces results, inks new deal

By |March 16th, 2017|Opinions|

Catalyst Pharmaceuticals ($CPRX) reported its fourth quarter and full year results. The company incurred a GAAP net loss of $18.07 million or $0.22 per basic and diluted share, compared to a GAAP net loss of $20.23 million or $0.25 per basic and diluted share, for the 2015 fiscal year.  For [...]

Premarket Biotech Digest – $TROV inks new deal, $PFE gets Chinese approval, $NVLN reports Q4 results

By |March 16th, 2017|Digest|

Shire PLC ($SHPG) announced that the European Medicines Agency has approved expanded indications for its hereditary angioedema treatment CINRYZE (C1 inhibitor [human]). The product may now be used for routine prevention of angioedema attacks in children as young as six years with severe and [...]

Arena Pharmaceuticals ($ARNA) Reports Q4 and Full Year Results

By |March 15th, 2017|Opinions|


Premarket Biotech Digest – $MRK receives FDA approval, $AZN reports +ve results, $BIOC inks new deal

By |March 15th, 2017|Digest|

Merck ($MRK) announced receiving the FDA approval for its  PD-1 inhibitor KEYTRUDA (pembrolizumab) to treat adult and pediatric patients with refractory classical Hodgkin lymphoma or who have relapsed after three or more prior lines of therapy. The FDA granted the approval based on the [...]

Peregrine Pharmaceuticals ($PPHM) reports Q3 Results

By |March 14th, 2017|Opinions|

Peregrine Pharmaceuticals Inc. ($PPHM) provides updates for its operations and financial results for the third quarter of the year. The company announced that its three clinical trials under the collaboration with the NCCN are advancing as planned. It also plans to continue the comprehensive biomarker analysis of data collected in [...]

Premarket Biotech Digest – $EDIT inks new deal, $AEMD reports +ve trial results, $PFE launches Zavicefta

By |March 14th, 2017|Digest|

Editas Medicine ($EDIT) announced inking a new exclusive R&D deal with Allergan ($AGN). The deal provides Allergan with an option to license up to five of EDIT's genome-editing ocular programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently in preclinical [...]

Vericel ($VCEL) reports fourth quarter results

By |March 13th, 2017|Opinions|

Vericel Corporation ($VCEL) announced its fourth quarter and full year financial results. The company reported that its total net revenues for the quarter ended December 31, 2016 were approximately $16.5 million, consisting of $12.7 million of Carticel® net revenue and $3.8 million of Epicel® net revenues. Its total net revenues [...]

Premarket Biotech Digest – $AMGN reports +ve trial results, $MYL inks settlement, $ZYNE completes enrollment

By |March 13th, 2017|Digest|

Amgen Inc. ($AMGN) announced the results of a late-stage study which showed that its injection Repatha significantly reduced the need for patients to undergo a procedure to reduce bad cholesterol. The news is expected to have positive impact on the stock price which is [...]

Immunomedics deal with Seattle Genetics is put on hold

By |March 10th, 2017|Opinions|

Immunomedics Inc. ($IMMU) is reported to have halted its deal with Seattle Genetics, which was announced on February 10th earlier this year. However, the collaboration was criticized by the activist firm venBio for providing little value to the Immunomedics shareholders. VenBio is the largest shareholder Immunomedics with 9.9 percent stake. Four [...]

Premarket Biotech Digest –$ACOR receives +ve patent ruling, $CUR reports positive data, $KTOV inks new deal

By |March 10th, 2017|Digest|

Acorda Therapeutics Inc. ($ACOR) stock jumped up as the company announced that  the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld all four patents challenged via the inter partes review (IPR) process.  These patents were Nos. 8,663,685 (the ‘685 patent), [...]

Medigus completes MUSE procedure in China

By |March 9th, 2017|Opinions|

Medigus Ltd. ($MDGS) announced that it has completed its first MUSE procedure in China.  the procedure was reported successful, with the patient encountering minimal discomfort during the procedure. The patient has since been released from the hospital, with no procedural complications.  Chris Rowland, CEO of Medigus said, “With the completion [...]

Premarket Biotech Digest – $VRX restructures, $APRI sells selective assets, $BIOL reports quarterly loss

By |March 9th, 2017|Digest|

Pfizer Inc. ($PFE) announced that the FDA has accepted its new drug applications (NDA) for its diabetes candidate, ertugliflozin as a monotherapy as well as two fixed-dose combination tablets. The company is developing the drug in collaboration with Merck & Co. Inc. The companies [...]

Mesoblast receives Fast Track Designation for Cell Therapy

By |March 8th, 2017|Opinions|

Mesoblast Limited ($MESO) reported that the United States Food and Drug Administration (FDA) has granted a Fast Track designation for the use of its cell therapy, MSC-100-IV. The treatment is designed to achieve improved overall response rate in children with steroid refractory acute Graft Versus Host Disease (aGVHD). The designation [...]

Premarket Biotech Digest – $ETRM reports loss, $RVNC completes patient enrollment, $BLCm gets Outperformer rating

By |March 8th, 2017|Digest|

TiGenix ($TIG) stock touched its 52 weeks high of $16.10 in its Tuesday trading session as the company announced receiving positive feedback from the U.S. Food and Drug Administration (FDA) on an improved protocol for its global Phase III trial for the treatment of [...]

GlaxoSmithKline ($GSK) reports positive results from Nucala trial

By |March 7th, 2017|Opinions|

GlaxoSmithKline plc ($GSK) announced data for its Nucala trial. The company said that patients with severe asthma, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, in [...]

Premarket Biotech Digest – $GALT reports +ve results, $IMUC receives FDA approval, $ETRM reports quarterly loss

By |March 7th, 2017|Digest|

Mesoblast Limited ($MESO) reported that the United States Food and Drug Administration (FDA) has granted a Fast Track designation for the use of its cell therapy, MSC-100-IV. The treatment is designed to achieve improved overall response rate in children with steroid refractory acute Graft [...]

Ionis Pharmaceuticals reports positive trial results

By |March 6th, 2017|Opinions|

Ionis Pharmaceuticals ($IONS) announced that the pivotal Phase 3 APPROACH study of volanesorsen met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronemia syndrome. The trial was being carried out by the company’s wholly owned subsidiary Akcea Therapeutics. The average incoming triglyceride level of patients in the [...]

Premarket Biotech Digest – $MSTX announces new deal, $TGTX reports +ve results, $SCYX postpones new study

By |March 6th, 2017|Digest|

TG Therapeutics ($TGTX) announced that a combination of its experimental cancer drug ublituximab and AbbVie Inc's Imbruvica outperformed Imbruvica alone in high-risk leukemia patients. The late-stage study involved adult patients with high-risk chronic lymphocytic leukemia, who had undergone at least one prior therapy. TG [...]